Neogap Therapeutics AB, a Swedish biotechnology company developing personalised immunotherapy for cancer treatment, announces that the first two patients have been treated in the company’s Phase I/II clinical trial. The trial investigates the safety and tolerability of a new, tailored treatment for advanced colorectal cancer, a disease with significant medical needs and limited treatment options.
Colorectal cancer affects two million people worldwide annually and is the third most common cancer type. For patients with metastatic disease, survival prospects are limited, underscoring the need for new, effective treatments. Neogap’s immunotherapy, pTTL (personalised Tumour Trained Lymphocytes), is being developed to address these challenges by offering a personalised treatment based on the patient’s own immune cells.
The clinical trial is being conducted in Sweden at Karolinska University Hospital and Danderyd’s Hospital in Stockholm, as well as Västmanland Hospital in Västerås. The trial targets patients with stage IV metastatic colorectal cancer. Patients are being continuously recruited nationwide, and a total of 12–16 patients will receive the treatment. The primary aim is to evaluate safety and tolerability while collecting data on treatment response.
“We are delighted to have treated the first patients – this is a significant milestone in our clinical trial and our mission to develop curative treatments for critically ill cancer patients. We have an outstanding trial team and look forward to the upcoming results,” says Samuel Svensson, CEO of Neogap Therapeutics.
About Neogap’s immunotherapy, pTTL
pTTL (personalised Tumour Trained Lymphocytes) is a cell-based immunotherapy that enhances the patient’s own T cells to fight cancer. The therapy combines sophisticated DNA sequencing with T-cell expansion to deliver a precision treatment for solid tumours. It is powered by Neogap’s patented technologies, PIOR® and EpiTCer®. The goal is to provide patients with a tailored and innovative therapy that meets their specific needs.
The clinical trial is conducted in collaboration with the following units:
- Phase 1 unit, Center for Clinical Cancer Studies, Theme Cancer, Karolinska University Hospital Solna, Stockholm, Sweden
- Medical Unit Cell therapy and Allogeneic stem cell transplantation (ME CAST), Theme Cancer, Karolinska University Hospital Huddinge, Stockholm, Sweden
- Medical Unit Pelvic cancer – Colorectal cancer, Theme Cancer, Karolinska University Hospital Solna, Stockholm, Sweden
- Department of Surgery, Västmanlands Hospital, Västerås, Sweden
- Department of Surgery and Urology, Danderyd’s Hospital, Stockholm, Sweden
Project reference number: 190185439 – NEOpTTL
Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or EISMEA. Neither the European Union nor the granting authority can be held responsible for them.